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Background: Nitric oxide (NO) is thought to play an important role in the pathophysiology of migraine. Infusion of
the nitrovasodilator glyceroltrinitrate (nitroglycerin, GTN), which mobilizes NO in the organism, is an approved
migraine model in humans. Calcitonin gene-related peptide (CGRP) is regarded as another key mediator in
migraine. Increased plasma levels of CGRP have been found during spontaneous as well as nitrovasodilator-induced
migraine attacks. The nociceptive processes and interactions underlying the NO and CGRP mediated headache are
poorly known but can be examined in animal experiments. In the present study we examined changes in
immunofluorescence of CGRP receptor components (CLR and RAMP1) and soluble guanylyl cyclase (sGC), the
intracellular receptor for NO, in rat trigeminal ganglia after pretreatment with GTN.
Methods: Isoflurane anaesthetised rats were intravenously infused with GTN (1 mg/kg) or saline for four hours and
two hours later the trigeminal ganglia were processed for immunohistochemistry. Different primary antibodies
recognizing CLR, RAMP1, CGRP and sGC coupled to fluorescent secondary antibodies were used to examine
immunoreactive cells in serial sections of trigeminal ganglia with epifluorescence and confocal laser scanning
microscopy. Several staining protocols were examined to yield optimized immunolabeling.
Results: In vehicle-treated animals, 42% of the trigeminal ganglion neurons were immunopositive for RAMP1 and
41% for CLR. After GTN pretreatment CLR-immunopositivity was unchanged, while there was an increase in
RAMP1-immunopositive neurons to 46%. RAMP1 and CLR immunoreactivity was also detected in satellite cells.
Neurons immunoreactive for sGC were on average smaller than sGC-immunonegative neurons. The percentage of
sGC-immunopositive neurons (51% after vehicle) was decreased after GTN infusion (48%).
Conclusions: Prolonged infusion of GTN caused increased fractions of RAMP1- and decreased fractions of
sGC-immunopositive neurons in the trigeminal ganglion. The observed alterations are likely immunophenotypic
correlates of the pathophysiological processes underlying nitrovasodilator-induced migraine attacks and indicate
that signalling via CGRP receptors but not sGC-mediated mechanisms may be enhanced through endogenous NO
production.
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Calcitonin gene related peptide (CGRP), which is expressed
in a major part of primary afferent neurons, is known
to play an important role in migraine and other primary
headaches [1-3]. Increased plasma levels of CGRP have
been found in the jugular vein of migraineurs during
spontaneous and nitrovasodilator-induced migraine attacks
[4-6]. Infusion of CGRP induced headaches in migraineurs,
partly fulfilling diagnostic criteria of migraine, but less
frequently in healthy persons [7,8]. Headaches induced
by CGRP infusion in healthy test persons were prevented
by the CGRP receptor antagonist olcegepant (BIBN4096BS)
[8]. Olcegepant and the later developed orally available
CGRP receptor antagonist telcagepant (MK-0974) proved
to be effective in the treatment of spontaneous migraine
attacks in well-designed clinical phase III studies [9,10].
In animal experiments topically applied CGRP receptor
antagonists (CGRP8-37 and olcegepant) inhibited increases
in meningeal blood flow elicited by periodic electrical field
stimulation of rat dura mater [11,12]. Spontaneous, heat-
evoked and nitrovasodilator-induced activity of rat spinal
trigeminal neurons with meningeal afferent input was
reduced when CGRP receptor antagonists were intra-
venously infused but local administration of olcegepant
onto meningeal receptive fields was ineffective [13,14].
However, the activity of neurons in the upper cervical
dorsal horn with meningeal afferent input was modulated
by microiontophoretic application of CGRP and CGRP re-
ceptor antagonists, which indicates a role for central CGRP
receptors in the control of spinal trigeminal activity [15].
The CGRP receptor consists of a large peptide with seven
transmembrane domains, the calcitonin receptor-like
receptor (CLR or CRLR) complemented by a single trans-
membrane domain, the receptor activity-modifying protein
1 (RAMP1). RAMP1 is responsible for the CGRP specifi-
city, whereas the association of CLR with other receptor
activity-modifying proteins like RAMP2 or RAMP3 com-
mutes the receptor to an adrenomedullin receptor [16]. For
the constitution of the functional CGRP receptor a third
intracellular component, the receptor component protein
(RCP), which couples the receptor to the intracellular signal
pathway through Gs proteins and adenylyl cyclase, is
essential [17]. CGRP receptors are widely expressed in the
central nervous system, in sensory ganglia and in blood
vessels [18]. In the trigeminal ganglion CGRP receptor
immunoreactivity has been found in neurons and satel-
lite glial cells [19-21].
Various studies indicate that NO plays also an essential
role in the pathogenesis of migraine [22,23]. Infusion of the
nitrovasodilator glycerol trinitrate (GTN, 0.5 μg/kg over
20 min) into migraineurs and healthy control persons
caused immediate and delayed headaches. Delayed head-
aches, which were typically experienced by migraineurs
peaking on average four hours after the infusion, weremore severe and fulfilled the diagnostic criteria for mi-
graine in half of the migraine group [24].
The links from NO to the pathophysiological processes
in migraine are not yet resolved. Soluble guanylyl cyclase
(sGC), a heterodimer consisting of an alpha and a beta sub-
unit [25,26], acts as the intracellular receptor for NO and
catalyses the conversion of GTP into the second messenger
3′,5′-cyclic guanosine monophosphate (cGMP) [27]. In rat
dural blood vessels increased sGC expression and ac-
tivity have been observed after subcutaneous injection
of 10 mg/kg GTN [28]. After pretreatment of rats with
GTN (250 μg/kg) the proportion of trigeminal ganglion
neurons immunoreactive for CGRP as well as for neuronal
NO synthase (nNOS) was increased [29]. Provided that this
reflects an increase in CGRP and NO production, it may re-
sult in elevated release of CGRP and NO from trigeminal
afferents and could contribute to the delayed activation of
rat spinal trigeminal neurons observed after nitrovasodilator
administration [14,30].
In the present study we asked if pretreatment with an
NO donor changes the equipment of trigeminal neurons
with receptor components of the CGRP and NO signalling
systems detected by immunofluorescence. The results
provide immunophenotypic evidence for a regulation of
RAMP1 and sGC at the level of the trigeminal ganglion.
Methods
Animals
Fourteen adult male Wistar rats (250–400 g) were used
for the study (Charles River, Wilmington, MA). Rats were
bred and kept on a 12 hour light 12 hour dark cycle with
unlimited access to water and food. The University of
Erlangen-Nürnberg and the local government approved the
experimental protocols. All procedures were conducted in
accordance with the European Communities Council dir-
ective of animal care and the German regulations of animal
welfare and treatment, and the experimental protocols were
reviewed by the local district government.
Preparation and tissue processing
Fourteen laboratory animals were initially anaesthetised in
a closed box by inhaling 4% isoflurane (Abbott, Wiesbaden,
Germany). Anaesthesia was maintained for six hours by
spontaneous breathing of humidified and oxygen-enriched
(30%) air with 2% isoflurane through a loosely fitted mask.
Rats were placed in prone position on a feedback-controlled
warming plate to maintain the body temperature of 37°C.
A catheter was introduced into the femoral vein to admin-
ister substances diluted in isotonic saline by a syringe
pump (Harvard Apparatus, March-Hugstetten, Germany).
The NO donor glyceroltrinitrate (GTN, Schwarz Pharma,
Monheim, Germany) was continuously applied intrave-
nously (i.v.) at a dose of 1 mg/kg bodyweight over four
hours. Control animals obtained isotonic saline as vehicle
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rate. All rats were kept anaesthetised for another period
of two hours receiving isotonic saline at an infusion rate
of 0.5 ml/h before being euthanized with an overdose of
Trapanal (Thiopental, Nycomed, Konstanz, Germany)
and perfused. Two rats were directly perfused after
anaesthesia without any infusions in order to control
possible effects of the anaesthetic procedures.
After thoracotomy, warm isotonic saline was perfused
through the left ventricle for about 3 minutes, in some of
the experiments followed by fixative (see below). The head
was separated from the body, divided in the sagittal plane
and the brain was removed. Both trigeminal ganglia were
freed from the wrapping dura mater and carefully excised
from the skull base. In those cases, in which the ganglia
remained unfixed for staining, they were mounted on a
base of frozen Tissue-Tek (Slee, Mainz, Germany) on
small plastic forms, then rapidly frozen in liquid nitro-
gen and stored in the freezer at −20°C. The ganglia were
cut into series of 20 μm thick longitudinal sections
using a cryostat (Leica, Bensheim, Germany). Sections
were mounted on alternated poly-L-lysine-coated slides
(Sigma-Aldrich, Steinheim, Germany) and dried for one
hour at room temperature before staining.
In order to optimize immunostaining we compared the
results of different fixation methods using the rabbit anti-
rat CLR antibody (see below). All fixation procedures
resulted in similar proportions of CLR-immunopositive
trigeminal ganglion neurons but both the contrast and
regularity of immunostaining showed some differences
(Figure 1A-E). The first fixation test group of rats was per-
fused after saline with Zamboni fixative (solution of 0.01%
picric acid and 4% paraformaldehyde (PFA) in 10 mM
phosphate-buffered saline (PBS), pH 7.4) for 5 min. The
removed ganglia were post-fixed in Zamboni for two
hours, stored in 10 mM PBS for 24 hours and kept in a
30% solution of sucrose in PBS for cryoprotection before
they were cut and immunostained at the next day
(Figure 1A). The second test group was perfused with a
solution of 4% PFA in 10 mM (PBS, pH 7.4) for 20
minutes, postfixed in the same fixation solution for two
hours and stored in 10 mM PBS for 24 hours. Cryo-
protection was accomplished in a 30% solution of sucrose
in PBS for one day (Figure 1B). The third test group was
perfused with a solution of 4% PFA in PBS for ~5 mi-
nutes, postfixed in Zamboni (2 h), stored in 10 mM PBS
for 24 hours and put in a 30% solution of sucrose in
PBS for cryoprotection for one day (Figure 1C). The
fourth test group of animals was perfused with isotonic
saline for about three minutes, the removed trigeminal
ganglia were rapidly frozen in liquid nitrogen and
sections were postfixed on slides in a mixture of metha-
nol and acetone (7:3) for ten minutes directly before
staining (Figure 1D).Unfixed cryopreserved trigeminal ganglia showed the
most consistent quality and the best contrast of stained
structures. Therefore, this method was used for quantifi-
cation of neurons (Figure 1E).Immunohistochemistry
The sources, characteristics, and dilutions of the primary
and secondary antibodies used in this study are listed in
Tables 1 and 2. After rinsing in phosphate-buffered
saline (PBS; 0.01 M, pH 7.4), the mounted sections were
preincubated for one hour at room temperature with a so-
lution of 5% donkey or goat serum (Dianova, Hamburg,
Germany), containing PBS/BSA/TX; composed of PBS,
0.5% Triton X-100 and 1% bovine serum albumin. Sec-
tions were rinsed in PBS for another five minutes before
incubating them with primary antibodies raised in rabbit
or goat and directed against CLR, RAMP1, sGC ß1, or
CGRP at room temperature overnight (characteristics and
dilutions see Table 1). Sections were washed with PBS
three times for five minutes and incubated with fluores-
cent secondary antibodies for 1 hour at room temperature.
Secondary antibodies were goat anti-rabbit IgG coupled to
indocarbocyanine (Cy3), donkey anti-goat IgG coupled to
Alexa Fluor 488, donkey anti-rabbit IgG coupled to Alexa
555 (see Table 2). Sections were rinsed again three times
for five minutes with PBS, coverslipped in Fluoromount G
(SouthernBiotech, Birmingham, AL), and stored at 4°C.
In selected immunostainings DAPI (4′,6′-diamidino-2-
phenylindole hydrochloride; Sigma-Aldrich, St. Louis) for
labelling of nuclear DNA was added at a concentration of
2 μg/ml to the secondary antibody.Controls
To verify the specificity of the immunohistochemical
reactions, every staining was controlled by omitting
primary antibodies in the first incubation fluid, and the
immunostaining was only accepted when these negative
controls did not show any specific staining. Preab-
sorption controls have been accomplished for the CLR
and RAMP1 primary antibodies in prior studies and
there was no staining with preabsorbed CLR or RAMP1
antibodies using their respective blocking peptides [19].
In case of the goat anti-sGC ß1 antibody, the pre-
absorption control showed no specific staining (sGC
peptide: sGC primary antibody 10:1). The anti-CGRP
primary antibody used was evaluated by an enzyme-
linked immunosorbent assay (ELISA; manufacturer’s
technical information) and produced a pattern of
CGRP-ir that was identical to previous descriptions
[29,31-33]. In addition, evidence for the specificity of
the goat anti-CGRP primary antibody resulted from vir-
tually identical stainings as reported with other CGRP
antibodies [34-36].
Figure 1 Confocal images of trigeminal ganglion sections treated with the rabbit anti-rat CLR antibody and the secondary goat
anti-rabbit antibody conjugated to Cy3 after different fixation methods. (A) Short Zamboni perfusion ~5 min, post-fixed in Zamboni for
two hours. (B) Perfusion with 4% paraformaldehyde (PFA) for 20 min and postfixation in 4% PFA (2 h). (C) Perfusion with 4% PFA for ~5 min,
postfixation in Zamboni (2 h). (D) Cryofixation, postfixation with methanol-acetone (7:3) for 10 min. (E) Cryofixation without any postfixation.
(F) Low-power micrograph of a trigeminal ganglion section, stained with azur methylene blue, with the ophthalmic (V1), maxillary (V2) and
mandibular division (V3), in which separate cell counts were made. Scale bars A-E = 100 μm; F = 1 mm.
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For a quantitative analysis of neurons immunopositive for
the relevant antigen, five longitudinal sections adjacent to
the center of each ganglion showing all three trigeminal
divisions, V1 (ophthalmic), V2 (maxillary) and V3 (man-
dibular), were selected for counting. Sections were taken
from both trigeminal ganglia. To avoid double counting of
neurons, every second section was omitted. The V1, V2
and V3 regions were analysed as a whole and also
separately (see Figure 1F). All sections showed a faintbackground staining, which served to count the whole cell
number. At least 33 neurons per anatomical region were
counted, i.e. more than 500 neurons per ganglion. CLR,
RAMP1, sGC ß1, CGRP, as well as double-stained neu-
rons in various combinations were counted by the investi-
gators, who were blinded to the treatment of rats using a
20× dry objective lens. In a sample of 10 sections both in-
vestigators (JN and KS) counted CLR-immunopositive
and -negative neurons independently from each other and
came to similar results (KS: 29% positive cells, total cell
Table 1 List of primary antibodies (all diluted in PBS/BSA/TX)
Antigen Host Antigen characteristics/epitope Reference number Producer Dilution
Calcitonin receptor-like receptor
(CLR)
Rabbit GYSHDCPTEHLNGK in the
C-terminal of human CLR
3152 Merck & Co., Inc. Rahway NJ, USA 1:1500
Calcitonin receptor-like receptor
(CLR)
Rabbit C-terminal of rat CLR 3155 Merck & Co., Inc. Rahway NJ, USA 1:500
Receptor activity modifying protein
(RAMP1)
Goat C-terminal of human RAMP1 844 Merck & Co., Inc. Rahway NJ, USA 1:100
Receptor activity modifying protein
(RAMP1)
Rabbit C-terminal of rat RAMP1 3158 Merck & Co., Inc. Rahway NJ, USA 1:2500
Soluble guanylyl cyclase (sGC ß1)
(C-13)
Goat Carboxy terminus of human
sGC ß1
sc-21310 Santa Cruz Biotechnology,




Goat Rat Tyr-CGRP (23–27) BT 17-2090-07 Biotrend, Cologne, Germany 1:100
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For the main experiments neurons were counted concor-
dantly by both investigators in same session.
Confocal microscopy and image processing
Sections were examined and images were obtained using a
LSM 780 confocal-laser scanning system (Carl Zeiss
MicroImaging GmbH, Jena, Germany) equipped with an
Argon laser (458, 488, 514 nm), a diode laser (405 nm), a
DPSS-laser (561 nm) and a HeNe-Laser (633 nm) (LASOS
Lasertechnik, Jena, Germany), mounted on an inverted
Axio Observer Z1. The filter settings of the confocal
scanner for single and double labeling were: 488 nm exci-
tation for Alexa 488 (beam splitter MBS 488, gritfilter
493–630 nm), 514 nm excitation for Cy3 (beam splitter
MBS 458/514, gritfilter 538–681 nm) and Alexa 555 (beam
splitter MBS 458/514, gritfilter 545–697 nm). Two dry ob-
jective lenses, (10× and 20× with numerical apertures of
0.3 and 0.8), two oil-immersion objective lenses (20× and
63× with numerical apertures of 0.8 and 1.4), and a 40×
water objective lens (numerical aperture 1.3) were used.
Electronic zoom factors varied between 1.0 and 1.4.
Sequential scanning and appropriate pinhole settings wereTable 2 List of secondary antibodies (all diluted in PBS/
BSA/TX)
Secondary antibody Conjugated to Producer Dilution
Donkey anti-goat Alexa 488 Molecular probes, 1:2000
Eugene, OR,
USA
Goat anti-rabbit Cy3 Dianova, 1:200
Hamburg,
Germany
Donkey anti-rabbit Alexa 555 Invitrogen, 1:1000
Carlsbad, CA,
USAused to minimize spectral bleed through. For examination
of co-localization of immunofluorescence, single optical
sections at the same focus plane were taken separately and
the two corresponding channels were merged. Adjustment
for contrast, brightness and evenness of illumination was
performed and exclusive areas of images were electro-
nically enlarged in order to document details. The number
of image pixels varied between 2048 × 2048 and 512 × 512
pixels. Channels of each picture were merged into a 12-bit
RGB tiff-file using confocal assistant software ZEN 2010.
For organising the final layouts and applying text and scale
bars CorelDraw (Corel, Dublin, Ireland) was used.
Statistical analysis
The percentage rate of neurons positive for CLR, RAMP1,
sGC ß1, CGRP, as well as co-localized CLR/RAMP1 and
sGC ß1/CGRP immunoreactivity was compared between
GTN and saline-treated animals. In addition we separately
analysed the distribution of cells immunopositive for these
proteins in medial (ophthalmic, V1) and lateral (maxillary,
V2 and mandibular, V3) regions of the trigeminal ganglion.
Statistical analysis was performed with Statistica software
(Tulsa, OK, USA). The nonparametric Chi-square test for
independent samples was used to compare the number
of immunopositive neurons between pretreatments. Sig-
nificance was defined as p < 0.05. Data are reported as
mean ± standard deviation (SD).
Results
Comparison of CLR and RAMP1 immunostaining using
different antibodies
Antibodies against human (CLR 3152 and RAMP1 844)
and rat (CLR 3155 and RAMP1 8158) CGRP receptor
components were tested (Figure 2A-D). Generally, in
neurons antibodies showed homogeneous or faintly
granulated immunofluorescence. The anti-human CLR
3152 antibody coupled to Alexa 488 revealed some
nuclear staining while the neuronal cell bodies lacked
Figure 2 Comparison of the CLR and RAMP1 immunofluorescence in trigeminal ganglia using different antibodies. (A) Rabbit anti-
human CLR antibody coupled to Alexa 488 (green) shows partly nuclear staining while neuronal cell bodies lack immunofluorescence. (B) Anti-
human RAMP1 antibody coupled to Alexa 488 (green) produced homogenous or granulated staining of neuronal cell plasma but no nucleus
staining. This antibody was used for the main experiments with cell counting. (C) Rabbit anti-rat CLR antibody coupled to Cy3 (red), resulting in
mostly homogenous staining. It was finally used for the experiments with cell counting. (D) Rabbit anti-rat RAMP1 coupled to Cy3 (red) caused
weak and less specific staining of neurons. Scale bars = 100 μm.
Seiler et al. The Journal of Headache and Pain 2013, 14:74 Page 6 of 14
http://www.thejournalofheadacheandpain.com/content/14/1/74fluorescence (Figure 2A). The anti rat CLR 3155 anti-
body coupled with Cy3 stained the whole cytoplasm
without any nucleus staining (Figure 2C). The staining
was constant and evenly distributed throughout the
whole ganglia. Therefore this antibody was selected for
quantitative analysis (see Figure 3D). The anti rat
RAMP1 3158 antibody coupled to Cy3 showed ambi-
guous staining, therefore a reliable distinction between
positive and negative neurons was not always possible
(Figure 2D). In contrast, the anti human RAMP1 844
antibody coupled to Alexa 488 showed clear and con-
stant neuronal staining throughout the whole ganglia
(Figure 2B); some neurons exhibited very intense fluo-
rescence, while others were less intensely stained; both
were evaluated as immunopositive. This RAMP1 anti-
body was selected for quantitative receptor analysis (see
Figure 3E), because it showed most frequently a consis-
tent quality of reliable staining, and in addition, due to
species distinctions, double labelling with the rabbit
anti-rat CLR 3155 antibody was easily possible. The anti
human RAMP1 844 antibody has previously been de-
monstrated to work well in rat tissue [19].Proportion of CLR and RAMP1-immunoreactive neurons
In the trigeminal ganglion, neuronal CLR- and RAMP1-
immunostaining produced homogenous or faintly granu-
lated immunofluorescence that was distributed over the
entire cytoplasm and spared the nucleus (Figure 3C-F).
Immunopositive neurons were located in all areas of the
trigeminal ganglion. In CLR-immunostained sections of
six saline-treated animals, 4618 neurons were counted,
1897 of which were identified as CLR-immunopositive
(41% ± 3,8), while among 4659 neurons of six GTN
treated animals 1975 neurons were positive (42% ± 4.5).
Chi square comparison of immunopositive to immu-
nonegative neurons showed no significant difference
between saline and GTN (p = 0.1999; Figure 4A). In
RAMP1-immunostained sections of the six saline-treated
animals 4967 neurons were counted, 2058 of which were
identified as RAMP1-immunopositive (42% ± 4.7), while
among 4880 neurons of the six GTN-treated animals
2255 neurons were immunopositive (46% ± 2.3). Chi
square comparison of immunopositive to immunonegative
neurons showed a significant difference between saline
and GTN (p < 0.001; Figure 4C). In the ganglia of the two
Figure 3 CLR and RAMP1 immunostaining of trigeminal ganglia. (A) CLR- and (B) RAMP1-negative controls (NC); primary antibodies were
omitted and no specific immunostaining is visible after incubation with the secondary antibodies coupled with Cy3 (A) or Alexa 488 (B). (C)
RAMP1 immunostaining (Alexa 488) without any pretreatment of the animals. (D) CLR coupled to Cy3 (red) (saline-treated animal) and (E) RAMP1
coupled to Alexa 488 (green) (GTN-treated animal) immunofluorescence in the trigeminal ganglion. The magnified inset in (D) shows a typical
CLR-immunopositive- and a CLR-immunonegative neuron. The magnified part of (E) in (F) illustrates the different intensity of the RAMP1
immunostaining of neurons. The neuron marked with * is a very intense RAMP1 immunopositive neuron compared to the neuron marked with °
but both were counted as immunopositive. (G-I) Double immunostaining using CLR and RAMP1 antibodies (GTN-treated animal). (G) CLR-
positive neurons in the red channel, (H) RAMP1-positive neurons in the green channel and (I) both receptor components in the merged image;
CLR and RAMP1 were colocalized in some neurons (yellow). Neurons exclusively immunopositive for CLR are extremly rare, in contrast to only
RAMP1-positive neurons (*). The magnification shows a neuron immunopositive for both receptor components. All images from cryofixed
trigeminal ganglia without any postfixation. Scale bars = 100 μm.
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rons, 330 of which were identified as CLR-immunopositive
(43% ± 0.7) and 1272 neurons, 518 of which were identi-
fied as RAMP1-immunopositive (41% ± 2.1). These pro-
portions of immunopositive neuron were not different to
the respective proportions in the saline treated animals
(Figure 4A and C).
Some neurons regarded to be immunopositive for
RAMP1 showed weaker immunofluorescence, while other
neurons showed a very intense staining (Figure 3F).
Therefore the very intense RAMP1 immunopositive neu-
rons were separately analysed in an additional counting.
In the six saline-treated animals we counted 4897 neu-
rons, 1319 of which were classified as very intenseRAMP1-immunopositive neurons (27% ± 8.9). In the six
GTN treated animals we counted 4738 neurons, 1417
of which were identified as very intense RAMP1-
immunopositive (30% ± 6.0). Chi square comparison of
immunopositive to immunonegative neurons showed
a significant difference between saline and GTN
(p = 0.0012; Figure 4C).
The proportions of immunoreactive neurons for CLR
and RAMP1 in the individual trigeminal ganglion divi-
sions, ophthalmic (V1), maxillary (V2) and mandibular
(V3) are shown in Table 3 and Figure 4B and D. A sig-
nificant effect of GTN pretreatment on the percentages
of RAMP1-immunopositive neurons was seen in V1 and
V2 but not in V3.
Figure 4 Quantitative analysis of CLR- and RAMP1-
immunopositive neurons in the trigeminal ganglion.
(A) Percentage of CLR-immunopositive neurons in untreated animals
(Control, n = 2), saline- (n = 6) and GTN-pretreated animals (n = 6).
(B) CLR-immunopositive neurons specified for the ophthalmic (V1),
maxillary (V2) and mandibular (V3) division of trigeminal ganglia in
saline and GTN-treated animals. (C) Percentage of RAMP1-
immunopositive neurons in the trigeminal ganglia of untreated
animals (Control, n = 2), saline- (n = 6) and GTN-pretreated animals
(n = 6). In the saline- and GTN-treated groups, intensely stained
RAMP1-positive neurons are also counted separately. (D) RAMP1-
positive neurons specified for V1, V2 and V3 in saline- and
GTN-treated animals. Error bars represent SD (n=6). * significant
difference to saline (Chi-square test of immunopositive
and –negative neurons).
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DAPI nucleus staining indicated that the trigeminal
ganglion in addition to neurons contains many small
cells, presumably satellite and Schwann cells. Neurons
were frequently surrounded by CLR- and RAMP1-
immunoreactive cell structures, which most likely rep-
resented satellite glial cells (Figure 5A-F). They were
comparable to similar CLR- and RAMP1-immunopositive
satellite cells described in previous publications [19,20].
Double CLR- and RAMP1-immunopositive neurons
Co-localised neurons were identified by CLR-immu-
nopositive staining in the red channel (Alexa-555) and
RAMP1-immunopositive staining in the green channel
(Alexa-488) (see Figure 3G-I). In the merged confocal im-
ages the double-positive neurons appeared either homoge-
neously or partly yellow, with some variation of intensity.
In ganglion sections from the six saline-treated animals,
2532 neurons were counted, 1057 of which were identified
as both CLR and RAMP1 immunopositive (42% ± 7.2).
Among 2357 neurons of six GTN-treated animals 933
neurons were positive for both receptor components
(40% ± 12.4). Chi square comparison of immunopositive
to immunonegative neurons showed no significant dif-
ference between saline and GTN (p = 0.1243). Indepen-
dent from treatment CLR- and RAMP1-immunoreactivity
was often co-localized in trigeminal neurons; some neu-
rons expressed only RAMP1, while CLR alone was rarely
found.
Soluble guanylate cyclase-immunoreactive neurons
Soluble guanylate cyclase-(sGC-)immunopositive neu-
rons were homogenously and mostly completely stained
by immunofluorescense but the nucleus was spared
(Figure 6C-F). Cells containing this marker were distri-
buted throughout the trigeminal ganglion.
In ganglion sections from the six saline-treated ani-
mals, 7537 neurons were counted, 3819 of which were
identified as sGC-immunopositive (51% ± 1.4), while




RAMP1/total (n) % SD (%) RAMP1/total (n) % SD (%) p-level
V1 605/1484 41% ± 5.7 714/1523 47% ± 5.6 0.0007
V2 632/1566 40% ± 6.2 762/1553 49% ± 6.5 0.0000




CLR/total (n) % SD (%) CLR/total (n) % SD (%) p-level
V1 593/1463 41% ± 6.8 820/1394 41% ± 3.3 0.7266
V2 517/1381 37% ± 6.4 606/1520 40% ± 3.3 0.1793
V3 787/1774 44% ± 7.1 795/1745 46% ± 7.4 0.4759
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neurons were found immunopositive (48% ± 2.6). Chi
square comparison showed a significant decrease in im-
munoreactive neurons after GTN compared to saline
pretreatment (p = 0.0041). The proportions of immuno-
reactive neurons for sGC in the trigeminal ganglion divi-
sions V1-V3 are shown in Table 4 and Figure 7A and B,Figure 5 Immunostaining of non-neuronal cells in the trigeminal gan
combined with DAPI (blue) nucleus staining. The magnified inset in (A) an
immunonegative neuron with a ring of CLR-immunopositive cells, which m
the DAPI staining (E) merged with the RAMP1 staining (F) shows a RAMP1
hemline, most likely representing satellite glial cells. Scale bars = 100 μm.illustrating that the difference between saline and GTN
pretreatment was mainly due to the significant decrease
in V3. In the ganglia of the two animals, which had not
obtained any pretreatment, we counted 2338 neurons,
1213 of which were identified as sGC immunopositive
(52% ± 1.9). No difference was seen to saline-treated ani-
mals (Figure 7A).glion. (A-C) CLR- (red) and (D-F) RAMP1-immunostaining (green)
d the DAPI staining (B) merged with the CLR staining (C) shows an
ost likely represent satellite glial cells. The magnified inset in (D) and
-immunopositive neuron with a RAMP1-immunopositive outer
Figure 6 sGC and CGRP immunostaining of trigeminal ganglia. (A) Negative control (NC) omitting the primary sGC antibody to control the
specificity of the immunostaining with Alexa 488. Neurons show no specific staining. (B) Preabsorption control (sGC-peptide: sGC-primary
antibody 10:1) with no specific staining. (C) sGC immunostaining using Alexa 488 as secondary antibody (green). In the magnified inset the
brightness is enhanced to show the negative neurons clearer. The image also shows that sGC-immunopositive neurons are smaller than the
sGC-immunonegative neurons. (D – F) sGC and CGRP double-immunostaining. (D) sGC-positive neurons in the green channel, (E) CGRP-positive
neurons in the red channel and (F) both channels merged with co-localised CGRP and sGC in some neurons. The magnified inset in
(D) – (F) shows a double-positive neuron. Scale bars = 100 μm.
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smaller than the sGC-immunonegative neurons, in the
saline as well as the GTN-treated group (Figure 7D).
Preabsorption control with the sGC ß1 peptide and
negative controls (see Materials and Methods) resulted
in no immunoreactivity (see Figure 6B).
Double CGRP- and sGC-immunopositive neurons
CGRP-immunopositive staining was visualised in the red
channel (Alexa-555) and sGC-immunopositive staining
in the green channel (Alexa-488). The CGRP immunore-
activity was mostly seen in small neurons homogenously
distributed or less frequently clustered around the nu-
cleus. In the merged confocal images the double positive
neurons appeared mostly homogenously yellow or clus-
tered more in the center of the cells around the spared
nucleus (Figure 6D-F). In six saline-treated animals,
2092 neurons were counted, 173 of which wereTable 4 Proportions of sGC-immunopositive neurons in the V
sGC
Saline GT
sGC/total % SD (%) sGC/t
V1 1253/2376 53% ± 6.9 1210/
V2 1172/2321 50% ± 5.1 1148/
V3 1394/2840 49% ± 4.2 1165/identified as only CGRP-immunopositive (8% ± 5,9) and
536 as both CGRP- and sGC-immunopositive (27% ±
5.1). Among 2002 neurons of six GTN treated animals
218 neurons were immunopositive only for CGRP (11% ±
4,7) and 522 were immunopositive for CGRP and sGC
(26% ± 5.5). Chi square comparison between saline and
GTN-treated groups of only CGRP-immunopositive and -
immunonegative neurons showed a significant increase
after GTN compared to saline pretretment (p = 0.0044),
though there was no significant difference in the samples
of double CGRP- and sGC-immunopositive neurons
(p = 0.7409) (Figure 7C).
Discussion
The aim of the present study was to investigate
immunophenotypic changes of trigeminal neurons after
NO-donor treatment. Herein we describe that CGRP
receptor components as well as the intracellular NO1, V2, V3 regions of the trigeminal ganglia
N Difference Saline-GTN
otal % SD (%) p-level
2272 53% ± 9.6 0.7219
2385 48% ± 5.6 0.1053
2635 44% ± 1.3 0.0003
Figure 7 Quantitative analysis of sGC-immunopositive neurons
in the trigeminal ganglion. (A) Percentage of neurons
immunopositive for sGC in the whole trigeminal ganglion and (B) in
V1, V2 and V3 divisions of the ganglion in control animals (n = 2),
saline-treated (n = 6) and GTN-treated (n = 6) animals. (C) Double
immunopositive neurons for CGRP and sGC in saline- und GTN-
treated animals and neurons only immunopositive for CGRP. (D) Cell
size distribution of sGC-positive and -negative neurons in the
trigeminal ganglion in saline- and GTN-treated animals. The sGC-
immunopositive neurons are mostly smaller than the sGC-
immunonegative neurons in the saline- as well as the GTN-treated
group. Error bars represent SD (n=6). * significant difference
(Chi-square test of immunopositive and –negative neurons).
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ies of the rat trigeminal ganglia. We found that after
GTN pretreatment the proportion of trigeminal ganglion
neurons immunopositive for the smaller CGRP receptor
component, RAMP1, was increased whereas the propor-
tion of neurons immunofluorescent for the large recep-
tor component, CLR, did not change. Furthermore, the
ratio of RAMP1-positive neurons was particularly in-
creased in the ophthalmic and maxillary regions of the
trigeminal ganglion, which resulted in a significant effect
across the whole ganglion. The reason for this diffe-
rential effect is unknown but may be associated with a
higher proportion of ophthalmic (V1) and maxillary
(V2) neurons compared to mandibular (V3) neurons in-
nervating intracranial structures.
In agreement with previous data in rat and human tri-
geminal ganglia [19,20], CLR and RAMP1 were mostly
co-localized in trigeminal ganglion neurons, however,
some neurons only expressed RAMP1, while CLR was
rarely found alone, irrespective of GTN pretreatment.
Since CLR and RAMP1 components are required for
forming functional CGRP receptors [37] we conclude
that the number of functional CGRP receptors may be
upregulated after NO donor pretreatment. In previous
studies the ratio of CLR-immunopositive trigeminal
ganglion neurons was reported to exceed the number of
RAMP1-positive neurons [19,20], which was not the
case in the present study, possibly due to different
fixation procedures or antibodies. Lennerz et al. specu-
lated therefore that RAMP1 is rate-limiting for the for-
mation of functional CGRP receptors, and the selective
regulation of RAMP1 could be an economic and time-
saving principle to upregulate the number of functional
CGRP receptors [20]. The present results do not directly
confirm this hypothesis, because the proportion of neu-
rons immunopositive for both receptor components was
unchanged, whereas the percentage of neurons select-
ively immunopositive for RAMP1 increased. It seems
plausible that an upregulation of CLR following RAMP1
upregulation in these neurons may occur with some
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mental time-scale. It is worth to mention that, consistent
with previous data in rat and human trigeminal ganglia
[19,20], CLR- and RAMP1-immunoreactivity was very
rarely co-localized with CGRP in same neurons, which
let us conclude that CGRP may signal from one primary
trigeminal afferent unit to another, whereas CGRP
autoreception is very unlikely.
Regarding the guanylyl cyclase (sGC) we observed de-
creased percentages of immunopositive neurons after
NO donor pretreatment. Furthermore, sGC-positive
neurons were particularly decreased in the mandibular
region of the trigeminal ganglion. Cells showing sGC
immunoreactivity were small sized, and the size distribu-
tion did not change after GTN pretreatment. Approxi-
mately one third of the trigeminal ganglion neurons were
double-immunopositive for CGRP and sGC. The ratio of
neurons double-immunopositive for sGC and CGRP was
not changed but the proportion of neurons expressing
CGRP but not sGC was increased in the GTN-treated
animals. An increase in CGRP-immunoreactive trigeminal
ganglion neurons together with an upregulation of neu-
rons immunoreactive to the neuronal NO synthase after
GTN pretreatment has previously been described [29].
Collectively these results suggest that systemic treatment
with an NO donor like GTN changes the expression pat-
tern of elements of the CGRP and NO signalling. Whereas
CGRP-mediated functions may be strengthened by an in-
crease in CGRP and functional CGRP receptors, intracellu-
lar NO signalling mediated by sGC may be downregulated,
possibly by negative feedback mechanisms.
Methodical and technical considerations
In this study anti-rat and anti-human antibodies against
the CGRP receptor proteins CLR and RAMP1 were
tested. For cell counts - the main part of our study - we
used the CLR anti-rat and the RAMP1 anti-human-anti-
bodies, because the immunoreactivity was consistent and
demonstrated the best contrast over all samples. The ex-
periments from Eftekhari et al. showed full cross-reactivity
between rat and human antibodies used in our study [19].
Eftekhari et al. produced and tested the human and rat
antibodies with preabsorption and Western blotting [19].
The specificity of the antibodies raised against human and
rat CLR and RAMP1 was confirmed in HEK293 cells with
stable expression of both the human CGRP receptor com-
ponents. Preabsorption with the respective blocking pep-
tides resulted in no immnunoreactivity of the antibodies
against CLR and RAMP1 in the human or rat trigeminal
ganglia [19]. The specificity of CLR and RAMP1 anti-
bodies was also confirmed by Eftekhari et al. with Western
blotting [19]. Human and rat CLR antibodies recognized
proteins consistent with the molecular weight of CLR and
RAMP1. Overall the primary antibodies displayed similarlocalization and distribution of the staining pattern in
human and rat trigeminal ganglia [19].
We detected in saline treated animals 41% CLR-ir
positive neurons, 42% RAMP1-ir positive neurons and
27% very intense RAMP1 immunopositive neurons at a
section thickness of 20 μm. Lennerz et al. found that 63%
of the neurons expressed CLR and 35% of the neurons
expressed RAMP1 [20]. The differences to our results
could be caused by the use of different primary antibodies
or variation in cell counting methods. However, in the
previous study using the same antibodies as in the present
study, Eftekhari et al. reported that 37% of the neurons
were immunopositive for CLR and 36% for RAMP1 at a
section thickness of 10–12 μm [19]. The thicker sections of
20 μm in our study could be a reason for the higher
numbers of detected RAMP1-immunopositive neurons. In
conclusion, the use of identical methods and antibodies
seems to be crucical for reliable quantitative comparisons
of immunoreactive neurons.
Distribution and regulation of the soluble guanylyl
cyclase
To our knowledge this is the first study that examined the
distribution of the sGC in the trigeminal ganglion. Ding
et al. showed that sGC is widespread in CNS in rats; both
sGC subunits are expressed together almost throughout
the whole brain [38]. They suggested that α and β sub-
units are generally coexpressed in most parts of the brain,
forming the enzymatically active heterodimers [38]. In the
present study the Santa Cruz antibody against the ß1 sub-
unit of the sGC was used. Based on Ding’s work, we as-
sume that our neurons immunopositive for the ß1 subunit
concomitantly express also the α subunit necessary for the
functional sGC molecule.
In a study in rat, Western blot analysis and im-
munhistochemistry after GTN treatment revealed an in-
crease of sGC expression and activity in dural blood
vessels, which peaked 30 minutes after the infusion and
returned to baseline levels after 60 minutes [28]. The inves-
tigators speculated that this phenomenon may be a me-
chanism to explain the subacute first headache peak
occurring within 20–30 minutes after GTN infusion in
healthy test persons [39]. However they did not investigate
expression and activity of the sGC after a longer post-GTN
period, which is of higher interest for the delayed head-
aches as seen in the clinical trials in migraineurs, who de-
veloped migraine-like pain after one to several hours [24].
In our study we observed decreased sGC-immunoreac-
tivity in the trigeminal ganglia six hours after GTN-
infusion. This may be an adaptive mechanism reducing
the effects of NO. An NO-induced desensitization of sGC
has been described in medullary interstitial cells, aortic
smooth muscle cells and cardiomyocytes [40-42]. Chronic
exposure to NO is known to reduce the sGC activity by
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transcription- and translations-dependent mechanisms in
smooth muscle cells [43]. After intracerebral injection of
inflammatory agents in rats decreased expression of sGC
at the protein and mRNA level in neural cells occurred
[44]. The decrease in sGC-immunoreactivity in our study
concerned particularly the mandibular (V3) region of the
trigeminal ganglia. The reason for this differential effect is
not clear but may be related to a differential upregulation
of CGRP receptor components - preferentially in V1 and
V2 regions of the ganglion. Provided that V3 contributes
less to the intracranial afferent innervation when compared
to V1 and V2, the decrease in sGC may serve other func-
tions than meningeal nociception or headache generation.
Conclusions
In summary we conclude that high NO levels may ini-
tiate down-regulation of the guanylyl cyclase. Our results
may be transferred to the pathophysiological long-term
processes rather than acute or subacute processes which
take place in nitrovasodilator-induced and/or sponta-
neous migraine attacks.
With regard to these adaptive effects of sGC it may be
speculated that the delayed excitatory actions of NO
donor infusion, i.e. delayed headaches [24] and increase
in neuronal activity [30] and c-fos activation [45] in the
spinal trigeminal nucleus, is not dependent on a sGC-
mediated effect of NO. Alternative mechanisms inclu-
ding actions of NO species like nitroxyl (HNO, NO-) via
TRP receptor channels have recently been reviewed in
detail [46].
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